Please login to the form below

Rethinking immunodermatology: Patient and market insights from leading KOLs and life science leaders

In our new publication, we speak to key opinion leaders and industry experts to uncover novel strategies for commercializing immunodermatology therapies in a crowded market landscape.

Today, there are more than 80 treatments in development for atopic dermatitis and psoriasis. The landscape is booming with treatment innovations. However, the rise in research and development has created a crowded market that healthcare professionals struggle to navigate. Dermatologists face an abundance of data and more complex barriers to access than ever before. These challenges often prevent them from prescribing novel treatments to patients.

In this report, we speak to key opinion leaders and biopharmaceutical executives to reveal insights on the market landscape and explore novel opportunities for life science companies to become valued partners for stakeholders they serve.

Download the eBook to learn:

  • Exclusive patient and clinical practice insights from leading dermatologists
  • Expert analysis on the latest treatment innovations
  • Market access advice for launching in crowded landscapes
  • How early portfolio strategy can drive faster patient access.

DOWNLOAD THE FULL EBOOK HERE

8th November 2021

Share

Tags

Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom

Latest content on this profile

Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health
Omnichannel scientific engagement and the use of archetypes to drive personalization
Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.
Fishawack Health
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Fishawack Health
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.
Fishawack Health
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset.
Fishawack Health